Related references
Note: Only part of the references are listed.Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
Matthias Guckenberger et al.
LANCET ONCOLOGY (2020)
Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases A Review
Rachel M. Glicksman et al.
JAMA ONCOLOGY (2020)
Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial
Robert Olson et al.
BMC CANCER (2020)
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer The ORIOLE Phase 2 Randomized Clinical Trial
Ryan Phillips et al.
JAMA ONCOLOGY (2020)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma et al.
LANCET (2019)
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
David A. Palma et al.
BMC CANCER (2019)
A phase III randomized-controlled, single-blind trial to improve quality of life with stereotactic body radiotherapy for patients with painful bone metastases (ROBOMET)
Carole Mercier et al.
BMC CANCER (2019)
Single versus Multifraction Stereotactic Radiosurgery for Large Brain Metastases: An International Meta-analysis of 24 Trials
Eric J. Lehrer et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Single Fraction Stereotactic Ablative Body Radiotherapy for Oligometastasis: Outcomes from 132 Consecutive Patients
S. Gandhidasan et al.
CLINICAL ONCOLOGY (2018)
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
Piet Ost et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
OLIGOCARE, the EORTC ESTRO initiative for oligometastasis: a pragmatic platform
P. Ost
RADIOTHERAPY AND ONCOLOGY (2018)
Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases
Darby Erler et al.
RADIOTHERAPY AND ONCOLOGY (2018)
A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial)
Carole Mercier et al.
RADIATION ONCOLOGY (2018)
Stereotactic Ablative Body Radiotherapy for Lung Metastases: Where is the Evidence and What are We Doing With It?
Shankar Siva et al.
SEMINARS IN RADIATION ONCOLOGY (2017)
Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust
Johannes M. Giesinger et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2016)
Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and Benefits
K. J. Ray et al.
CLINICAL ONCOLOGY (2015)
Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
Colleen M. Costelloe et al.
Journal of Cancer (2012)
Stereotactic body radiation therapy: The report of AAPM Task Group 101
Stanley H. Benedict et al.
MEDICAL PHYSICS (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Richard L. Wahl et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer
Robert Timmerman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Share Paper
